Biofrontera (BFRI) Set to Announce Quarterly Earnings on Wednesday

Biofrontera (NASDAQ:BFRI) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Biofrontera to post earnings of ($0.22) per share and revenue of $8.25 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 10:00 AM ET.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $9.50 million. On average, analysts expect Biofrontera to post ($0.60) EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Biofrontera Price Performance

BFRI opened at $0.89 on Wednesday. Biofrontera has a 12-month low of $0.55 and a 12-month high of $1.66. The business has a 50 day moving average of $1.13 and a 200-day moving average of $1.03. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BFRI. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biofrontera in a report on Tuesday, October 13th. Finally, Wall Street Zen cut shares of Biofrontera from a “buy” rating to a “hold” rating in a research report on Sunday, September 20th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Biofrontera Company Profile

Biofrontera Inc (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers.

Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.